Seattle Genetics Company Profile (NASDAQ:SGEN)

About Seattle Genetics

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SGEN
  • CUSIP: 81257810
Key Metrics:
  • Previous Close: $51.60
  • 50 Day Moving Average: $52.77
  • 200 Day Moving Average: $43.88
  • 52-Week Range: $140,516,000.00 - $26.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -59.10
  • P/E Growth: -3.12
  • Market Cap: $7.14B
  • Outstanding Shares: 140,516,000
  • Beta: 2.13
  • Net Margins: -27.21%
  • Return on Equity: -15.29%
  • Return on Assets: -11.79%
  • Current Ratio: 5.88%
  • Quick Ratio: 5.32%
Additional Links:
Companies Related to Seattle Genetics:

Analyst Ratings

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.47)
Consensus Price Target: $53.15 (4.57% upside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
DateFirmActionRatingPrice TargetDetails
10/10/2016RBC Capital MarketsReiterated RatingOutperform$55.00 -> $62.00View Rating Details
10/10/2016Leerink SwannReiterated RatingOutperform$62.00View Rating Details
10/10/2016Royal Bank Of CanadaBoost Price TargetOutperform$55.00 -> $62.00View Rating Details
9/16/2016Goldman Sachs Group Inc.DowngradeNeutral -> SellView Rating Details
9/7/2016Morgan StanleyInitiated CoverageOverweight$60.00View Rating Details
7/27/2016Barclays PLCBoost Price TargetOverweight$48.00 -> $53.00View Rating Details
7/27/2016SunTrust Banks Inc.Boost Price TargetNeutral$34.00 -> $38.00View Rating Details
7/27/2016Cantor FitzgeraldDowngradeBuy -> Hold$43.00View Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
6/29/2016Needham & Company LLCReiterated RatingBuy$60.00 -> $72.00View Rating Details
6/13/2016HC WainwrightReiterated RatingBuy$65.00View Rating Details
5/19/2016Cowen and CompanyReiterated RatingHoldView Rating Details
2/11/2016Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
2/10/2016Piper Jaffray Cos.Lower Price TargetNeutral$44.00 -> $33.00View Rating Details
2/10/2016JPMorgan Chase & Co.Lower Price TargetNeutral$45.00 -> $43.00View Rating Details
8/25/2015William BlairReiterated RatingBuyView Rating Details
2/11/2015Bank of America Corp.Reiterated RatingSellView Rating Details
2/9/2015Jefferies GroupSet Price TargetBuy$53.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Seattle Genetics (NASDAQ:SGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016Q316($0.29)$4.34 millionListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
Current Year EPS Consensus Estimate: $-1.00 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.29)($0.29)($0.29)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)


Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Seattle Genetics (NASDAQ:SGEN)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 97.93%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
DateHeadline logoSell Recommendations For Seattle Genetics, Inc. (NASDAQ:SGEN) At 0 - Investor Newswire (NASDAQ:SGEN) - October 21 at 7:19 PM logoSeattle Genetics (SGEN) Updates on Multiple Presentations Made at ISHL (NASDAQ:SGEN) - October 21 at 10:52 AM logoSeattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016 (NASDAQ:SGEN) - October 20 at 7:35 PM
News IconScorching Hot Biotech Stocks Tape: Ariad Pharmaceuticals (ARIA ... - The Independent Republic (NASDAQ:SGEN) - October 19 at 2:17 PM
News IconWhat's in Seattle Genetics, Inc. After Today's Bullish Options Activity? - Frisco Fastball (NASDAQ:SGEN) - October 19 at 2:17 PM logoSeattle Genetics creates new C-suite role as it seeks profitability (NASDAQ:SGEN) - October 17 at 7:07 PM logoSeattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : October 17, 2016 (NASDAQ:SGEN) - October 17 at 12:31 PM
News IconUpdate on Seattle Genetics, Inc. (NASDAQ:SGEN) for the day (NASDAQ:SGEN) - October 15 at 12:00 PM
News IconHot Biotech Stocks To Watch Right Now: Opko Health, Inc. (OPK), Seattle Genetics, Inc. (SGEN) - The Independent Republic (NASDAQ:SGEN) - October 14 at 7:03 PM
News IconTrading the Biotech News: Seattle Genetics, Inc. (NASDAQ:SGEN ... - The Voice Registrar (NASDAQ:SGEN) - October 14 at 7:03 PM logoSEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:SGEN) - October 12 at 7:14 PM logoSeattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress (NASDAQ:SGEN) - October 12 at 9:36 AM
News IconComparing Actinium's Actimab-A To Seattle Genetics' SGN-CD33A (NASDAQ:SGEN) - October 11 at 8:12 PM logoSGEN Crosses Above Average Analyst Target (NASDAQ:SGEN) - October 11 at 8:12 PM logoSeattle Genetics, Inc. 11.1% Potential Upside Now Implied by RBC ... - DirectorsTalk Interviews (NASDAQ:SGEN) - October 11 at 2:29 PM
News IconPutting Seattle Genetics, Inc. (NASDAQ:SGEN) Shares in the Spotlight: Analyst's Take - Yankee Analysts (NASDAQ:SGEN) - October 8 at 6:41 PM
News IconSeattle Genetics, Inc. (NASDAQ:SGEN) earnings expectations - The Independent Republic (NASDAQ:SGEN) - October 8 at 6:41 PM logoLeerink Says Seattle Genetics' (SGEN) Pipeline Value Drivers Still Underappreciated - (NASDAQ:SGEN) - October 8 at 6:41 PM logoLeerink Says Seattle Genetics' (SGEN) Pipeline Value Drivers Still Underappreciated (NASDAQ:SGEN) - October 7 at 6:55 PM logoBRIEF-Seattle Genetics, Agensys highlights promising Enfortumab Vedotin, ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress (NASDAQ:SGEN) - October 7 at 12:28 PM
News IconSeattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin ... (NASDAQ:SGEN) - October 7 at 12:28 PM
News IconCBS 58 - Seattle Genetics to Host Conference Call and Webcast Discussion (NASDAQ:SGEN) - October 7 at 12:28 PM logoSeattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO ... (NASDAQ:SGEN) - October 7 at 12:28 PM
News IconSeattle Genetics, Inc. (NASDAQ:SGEN) Consensus Estimates Update: Consensus Vs. Actual - Yankee Analysts (NASDAQ:SGEN) - October 6 at 12:50 PM
News IconRating Sentiment Change: Were Analysts Bullish Seattle Genetics, Inc. (NASDAQ:SGEN) This Week? - MoneyMakingArticles (NASDAQ:SGEN) - October 6 at 12:50 PM logoSeattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2016 Financial Results on October 27, 2016 (NASDAQ:SGEN) - October 6 at 12:50 PM logoSeattle Genetics (SGEN) Names New CTO, SVP (NASDAQ:SGEN) - October 5 at 12:35 PM logoSeattle Genetics (SGEN) Names New CTO, SVP - (NASDAQ:SGEN) - October 4 at 6:50 PM
News IconDetailed examination of the indolent lymphoma pipeline H2 2016 market therapeutics development research (NASDAQ:SGEN) - October 4 at 11:57 AM logoSeattle Genetics Announces Executive Promotions and Leadership Appointment (NASDAQ:SGEN) - October 4 at 11:57 AM
News IconBroker Changes For Seattle Genetics, Inc. (NASDAQ:SGEN ... - NewsDen (NASDAQ:SGEN) - October 3 at 11:55 AM
News IconAnalyst Target Update on Seattle Genetics, Inc. (NASDAQ:SGEN) - Recall News (NASDAQ:SGEN) - October 3 at 11:55 AM
News IconHot Biotech Stocks Recap: Seattle Genetics (NASDAQ:SGEN), Portola Pharmaceuticals (NASDAQ:PTLA) - The Voice Registrar (NASDAQ:SGEN) - October 3 at 11:55 AM
News IconTime To Put On The Watch List? - Seattle Genetics (NASDAQ:SGEN), XOMA (NASDAQ:XOMA) - The Voice Registrar (NASDAQ:SGEN) - October 1 at 8:00 AM logoSeattle Genetics : Assigned Patent (NASDAQ:SGEN) - September 30 at 2:47 PM logoSeattle Genetics : Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia (NASDAQ:SGEN) - September 29 at 7:09 PM
News IconWhich way Seattle Genetics, Inc. (NASDAQ:SGEN) earnings may go - The Voice Registrar (NASDAQ:SGEN) - September 28 at 12:29 PM
News IconHistory of Seattle Genetics, Inc. (NASDAQ:SGEN) stock price after earnings - The Independent Republic (NASDAQ:SGEN) - September 27 at 11:54 AM logoTwo Cancer Biotechs See Bullish Insider Buying - Barron's - Barron's (NASDAQ:SGEN) - September 27 at 11:54 AM
News IconIntraday Active Biotech Stocks News: Arrowhead Pharmaceuticals ... - The Voice Registrar (NASDAQ:SGEN) - September 22 at 6:55 PM logoSeattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia (NASDAQ:SGEN) - September 19 at 11:50 AM logo8:01 am Seattle Genetics initiates phase 1 clinical trial of SGN-CD123A for patients with relapsed or refractory acute myeloid leukemia (NASDAQ:SGEN) - September 19 at 11:50 AM logoSeattle Genetics Inc (SGEN): Baker Bros. Advisors Raises Stake - Insider Monkey (blog) (NASDAQ:SGEN) - September 17 at 6:44 PM
News IconStock Price Targets in Spotlight: Seattle Genetics, Inc. (NASDAQ ... - Yankee Analysts (NASDAQ:SGEN) - September 16 at 6:59 PM logoGlobal Payments Inc. (NYSE:GPN), Seattle Genetics, Inc. (NASDAQ ... - Benzinga (NASDAQ:SGEN) - September 16 at 6:59 PM
News IconSeattle Genetics (SGEN) is Upgraded by Goldman to Neutral (NASDAQ:SGEN) - September 16 at 10:50 AM
News IconSeattle Genetics Inc (SGEN): Baker Bros. Advisors Raises Stake (NASDAQ:SGEN) - September 16 at 8:46 AM logoSeattle Genetics No Longer On Goldman Sachs' Sell List | Benzinga - Benzinga (NASDAQ:SGEN) - September 15 at 7:22 PM
News IconIntraday Active Biotech Stocks News: Seattle Genetics, Inc. (NASDAQ:SGEN), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:SGEN) - September 15 at 10:55 AM logoSeattle Genetics No Longer On Goldman Sachs' Sell List (NASDAQ:SGEN) - September 15 at 10:22 AM


Seattle Genetics (NASDAQ:SGEN) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff